Results 111 to 120 of about 990,352 (302)

Inhibition of monocyte complement receptor enhancement by low molecular weight material from human lung cancers [PDF]

open access: yes, 1981
We have studied the effect of dialysates from lung cancer homogenates to alter both the expression of complement (C3b) receptors per se and also to inhibit leucoattractant-induced enhancement of complement rosettes on monocytes from healthy individuals ...
Kay, A B, Abell, C A, Glass, E J
core  

IgG and C3 receptors on polymorphonuclear leukocytes in phagocytosis. Role of C3-receptors in the attachement and ingestion phases

open access: yes, 1977
The role of IgG and complement (C3) receptors in the adhesion and ingestion phases of immune complexes by normal human polymorphonuclear leukocytes (PMN) were examined.
P. Borzini   +3 more
core   +2 more sources

Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex

open access: yesJournal of Neuroinflammation, 2018
Background Exposure of the developing brain to immune mediators, including antibodies, is postulated to increase risk for neurodevelopmental disorders and neurodegenerative disease.
Marianna Stamou   +4 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

IgG receptors and their role in antibody trafficking

open access: yes, 2023
Immunoglobulins (Ig) are the results of an adaptive immune response and link humoral and cellular immunity in host defence with IgG being the most abundant of the Ig classes.
Brinkhaus, Maximilian
core  

Signaling transduction by IgG receptors.

open access: yesChinese medical journal, 2003
To review and summarize literature regarding stimulatory and inhibitory signaling pathways from different types of Fc gamma receptors (FcgammaRs).Articles were obtained from Medline from January 1991 to April 2002.Over 100 English language papers and reviews published over the last 11 years were selected.Stimulatory Fcgamma receptors include FcgammaRI,
Luanfeng, Pan, Peng, Pei
openaire   +1 more source

Cholinergic autoantibodies from primary Sjögren′s syndrome inhibit mucin production via phospholipase C and cyclooxygenase-2 in the rat submandibular gland

open access: yesDental Research Journal, 2011
Background: Patients with primary Sjögren′s syndrome (pSS) produce functional IgG against cholinoreceptor of exocrine glands modifying their activity.
Daniela Passafaro   +3 more
doaj  

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

FITC and PE detection after anti-IgG-FITC staining.

open access: yes, 2016
FITC and PE detection after anti-IgG-FITC staining.
Ana Cristina Martins de Almeida Nogueira (3390941)   +5 more
core   +1 more source

MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives The study aimed to characterize the clinical features, etiologies, and outcomes of isolated, first‐time pediatric ON in the post‐MOG‐IgG era. Methods This was a single‐center retrospective cohort study at Texas Children's Hospital of patients diagnosed with first‐time ON between 2018–2024, with follow‐up data collected through 2025.
Chaitanya Aduru   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy